Shares of Savient Pharmaceuticals Inc. (SVNT) are higher on the session by 29%, currently trading at $19.03. The biotechnology company based in East Brunswick, New Jersey, announced that the FDA had approved its gout treatment Krystexxa, a drug that treats a type of arthritis, which analysts estimate may generate about $1 billion a year.
Savient stated that it expected Krystexxa to be available by prescription in the U.S. later this year.
From a technical analysis perspective: SVNT shares closed at $14.76 in the last trading session and opened today at $18.20. Savient has currently a trading volume of over 17 million shares, which is more than than ten times the ticker’s daily average of 798K.
SVNT, whose stock today hit its highest point in about two years, despite the co.’s negative ROA, ROE and trailing tm/operating margin, is trading well above its 50 and 200 day moving average of $14.39 and $13.75, respectively. SVNT’s 52 week range is $11.20 – $19.18.
Disclosure: No Position